Compare SGHC & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | ACLX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.7B |
| IPO Year | 2021 | 2022 |
| Metric | SGHC | ACLX |
|---|---|---|
| Price | $12.98 | $115.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 15 |
| Target Price | $17.33 | ★ $118.17 |
| AVG Volume (30 Days) | ★ 3.3M | 1.4M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $16.09 | $342.39 |
| Revenue Next Year | $9.73 | $170.71 |
| P/E Ratio | $20.80 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.08 | $47.86 |
| 52 Week High | $14.38 | $115.14 |
| Indicator | SGHC | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 70.30 | 79.86 |
| Support Level | $10.18 | $63.46 |
| Resistance Level | $14.38 | N/A |
| Average True Range (ATR) | 0.57 | 0.11 |
| MACD | 0.11 | -0.62 |
| Stochastic Oscillator | 82.82 | 84.28 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.